MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab.
Mehdi Hamadani
No relevant relationships to disclose
Andres Forero
Research Funding - MedImmune
Thomas J. Kipps
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Michelle A. Fanale
Research Funding - MedImmune
Antonio Cuneo
Research Funding - MedImmune
Jaime Perez de Oteyza
Research Funding - MedImmune
Douglas Gladstone
Honoraria - MedImmune
Research Funding - MedImmune
Expert Testimony - AstraZeneca
Trishna Goswami
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Research Funding - MedImmune
Ramy A. Ibrahim
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Meina Liang
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Steven Eck
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Nairouz Elgeioushi
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Ronald Herbst
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Bruce D. Cheson
Research Funding - MedImmune